Vorasidenib
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H13ClF6N6 |
Molar mass | 414.74 g·mol−1 |
3D model (JSmol) | |
| |
|
Vorasidenib is an experimental anti-cancer medication for the treatment of low-grade glioma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), which are mutated in several forms of cancer.[1] In a phase-III-trial, it was shown to prolong progression-free survival in patients with IDH1- or IDH2-mutant low-grade glioma.[2]
References
- ^ "Vorasidenib compound summary". pubchem. 2 September 2023. Retrieved 6 September 2023.
- ^ Mellinghoff, Ingo K.; et al. (2023-08-17), "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma", New England Journal of Medicine, vol. 389, no. 7, pp. 389–601, doi:10.1056/NEJMoa2304194, PMC 5900343, PMID 29670690
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Articles without KEGG source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Chloroarenes
- Pyridines
- Trifluoromethyl compounds
- Triazines
- Experimental cancer drugs
- All stub articles
- Pharmacology stubs